Why Midlife Biology Is the Missing Variable in Leadership Performance

By Julie Ashlock aka Jules

We are building economic strategy on incomplete data.

Women now represent nearly 40 percent of global entrepreneurs. In the United States alone, women owned businesses generate more than 1.8 trillion dollars in annual revenue. Globally, women are founding companies at record rates and stepping into executive leadership across finance, technology, healthcare, manufacturing, and policy.

Their influence is no longer emerging. It is structural.

And yet we continue to ignore one of the most predictable variables influencing their performance.

Biology.

A substantial number of women leading today are navigating midlife physiological shifts that directly affect cognitive clarity, stress resilience, sleep architecture, metabolic efficiency, vascular health, and emotional regulation. These are not peripheral concerns. They are executive performance drivers.

Every year, millions of women enter midlife while simultaneously occupying peak leadership roles. Women over forty five represent one of the fastest growing segments of the leadership pipeline. They are founders scaling companies, executives guiding large organizations, and decision makers allocating capital.

At the exact moment influence expands, physiology shifts.

And we are not designing leadership strategies around that reality.

The economic implications are not theoretical. Women over forty contribute trillions in workforce productivity and enterprise value globally. If even a fraction of that leadership capacity is compromised by preventable physiological instability, the cumulative effect is measurable. Productivity dips. Strategic execution slows. Burnout accelerates. Exit rates increase. Institutional knowledge is lost.

When leadership sustainability falters, economic systems absorb the cost.

In boardrooms and founder communities, we discuss scale, capital, systems, innovation, and mindset. When performance fluctuates, the solution is sharper productivity systems or stronger discipline. Rarely do we examine the internal physiology shaping output.

Estrogen regulates far more than reproduction. It influences neurotransmitter balance, stress response, inflammation, sleep quality, insulin sensitivity, and vascular stability. As levels fluctuate and decline during midlife, cortisol response shifts. Recovery narrows. Sleep fragments. Blood sugar variability increases. Stress tolerance tightens.

These shifts are biological. They are measurable. And they influence how leaders think, decide, and respond under pressure.

Consider a founder scaling rapidly. Investor expectations rise. Teams expand. Strategic pivots accelerate. Simultaneously, sleep becomes inconsistent. Stress chemistry stays elevated longer. Energy fluctuates across the day.

On paper, nothing changes. In practice, cognitive endurance shortens. Decision speed softens. Emotional regulation requires more effort. Recovery takes longer.

Each change appears minor. Over time, they compound.

In high stakes leadership, marginal losses matter.

Yet business culture often interprets these shifts as personal failure. A dip in energy becomes a discipline issue. Brain fog becomes a distraction. Heightened stress becomes insufficient resilience. The response is self correction instead of system recalibration.

After more than seventeen years in human performance work with high achieving women, I have seen this pattern repeatedly. Leaders question their competence when the variable they are overlooking is physiological, not intellectual.

The cost extends beyond individual careers.

Leadership is sustained decision making under pressure. It demands clarity, calibrated risk assessment, strategic foresight, and endurance. If the internal systems supporting those functions are unstable, performance becomes inconsistent. Momentum slows. Burnout risk rises. Retention suffers. Innovation contracts.

When a meaningful portion of the executive and entrepreneurial workforce operates with unmanaged physiological disruption, the ripple effects are not isolated. They influence corporate stability, succession planning, long term innovation cycles, and national productivity metrics. Economic performance is a reflection of human performance.

We do not design infrastructure without accounting for environmental conditions. We do not design technology without accounting for system capacity. Yet we design leadership models as if physiology remains static across decades.

These are operational variables.

There is a strategic opportunity embedded in this conversation that most organizations have not yet recognized.

Forward thinking companies invest heavily in leadership development, executive coaching, succession planning, and resilience training. Billions are spent globally on optimizing performance. Yet almost none of those frameworks account for predictable midlife physiological shifts in women.

This gap represents both risk and opportunity.

Risk, because unaddressed physiological disruption increases burnout probability, decision fatigue, and attrition at the exact stage when women hold critical institutional knowledge and high level authority.

Opportunity, because organizations that normalize performance biology and integrate physiological literacy into leadership infrastructure will retain top talent longer, stabilize executive output, and reduce preventable volatility in performance cycles.

This is not about accommodation.

It is about optimization.

It is about protecting long term return on leadership investment.

There is also a cultural silence embedded here. Women have long minimized biological transitions in professional spaces. Hormonal shifts are managed privately while performance expectations remain constant. The implicit expectation is that strong leaders perform as if nothing is changing.

But strength is not denial.

Strength is adaptation.

Markets evolve. Technology evolves. Strategy evolves. Physiology evolves. Leadership architecture must evolve with it.

As women expand their presence across executive offices, entrepreneurial ecosystems, and capital markets, performance sustainability must become part of economic strategy. Ignoring predictable biological transitions does not signal resilience. It signals incomplete system design.

Midlife biology is not a vulnerability to conceal.

It is a variable to optimize.

The future of female leadership is physiological.

And because women now shape a significant share of global economic output, this conversation does not belong on the margins.

It belongs in boardrooms.

It belongs in investment strategy.

It belongs in leadership development frameworks.

It belongs in economic policy conversations.

If we want sustainable growth across the global economy, we must design for the biology of the leaders driving it.

Anything less is not progressive.

It is inefficient.

Connect With Jules

www.linkedin.com/in/julieashlock